therapies · education ·
PEMF Beat Placebo For Knee Pain In One Trial. A Meta-Analysis Says Function, Not Pain
A double-blind trial, a pooled analysis that partly disagrees with it, and a large negative trial in fractures. All three belong in the same article.
Pulsed electromagnetic field therapy is sold with more confidence than almost anything else in the wellness equipment aisle, and it has a genuinely mixed evidence base underneath it.
Mixed does not mean worthless. It means the answer changes depending on what you are asking it to do.
The trial that makes the case
Sixty-six patients with radiographic knee osteoarthritis and persistent pain above 40mm on a visual analogue scale were randomized one-to-one to a wearable PEMF device or an identical placebo, double-blind, and told to use it 12 hours daily for one month. Sixty completed (Bagnato et al., Rheumatology, 2016).
After a month, PEMF produced a significant reduction in visual analogue pain and WOMAC scores against placebo, with pain tolerance and physical health also improving.
The effect on the pain scale was -0.73 (95% CI -1.24 to -0.19).
And the number we find most interesting, because it is a decision rather than a score: 26% of the PEMF group stopped their NSAID or analgesic therapy. No adverse events were detected.
One honest note the headline usually drops. The WOMAC effect size was -0.34, with an interval of -0.85 to 0.17. That crosses zero. The pain scale result held; that one did not.
The pooled analysis that partly disagrees
Eight randomized controlled trials, 421 patients, all comparing classical PEMF against placebo in knee osteoarthritis (Chen et al., Journal of Rehabilitation Medicine, 2019).
| Outcome | Result |
|---|---|
| Physical function | Improved, WMD -5.28 (95% CI -9.45 to -1.11), p = 0.01 |
| WOMAC total score | No significant advantage, p = 0.06 |
| WOMAC pain score | No significant advantage, p = 0.09 |
| Visual analogue pain | No significant advantage, p = 0.15 |
| WOMAC stiffness | No significant advantage, p = 0.1 |
So the pooled verdict is narrower than the single trial: function yes, pain and stiffness no.
That is the pattern we keep meeting on this site. A promising single trial, then a pooled analysis that trims it. When the two disagree, we go with the pooling, and we say which parts survived.
The trial nobody quotes
Two hundred and fifty-nine patients with acute tibial shaft fractures across six trauma hospitals were randomized, double-blind, to active or externally identical inactive PEMF devices, worn 10 hours daily for 12 weeks (Adie et al., Journal of Bone and Joint Surgery, 2011).
The result was flatly negative. Sixteen events in the active group, fifteen in the inactive group, risk ratio 1.02, p = 0.72. No difference in surgical intervention for any reason, radiographic union, or patient-reported function.
Adjuvant pulsed electromagnetic field stimulation does not prevent secondary surgical interventions for delayed union or nonunion and does not improve radiographic union or patient-reported functional outcomes in patients with acute tibial shaft fractures.
Adie et al., Journal of Bone and Joint Surgery, 2011
That is a well-run, well-powered, double-blind trial finding nothing, and it belongs in any honest summary of this therapy.
How to hold three results that disagree
They are not actually in conflict. They are answering different questions.
Different conditions. Knee osteoarthritis and an acute tibial fracture are not the same problem, and there is no reason a therapy should work on both.
Different devices and parameters. The meta-analysis authors end by calling for trials to determine the optimal parameters and treatment regimen, which is a polite way of saying the field has not agreed what dose is correct. Frequency, intensity, waveform and duration all vary between studies.
Different outcomes. Function and pain are measured separately and they moved separately.
So our reading: PEMF has real, replicated evidence for physical function in knee osteoarthritis, weaker and inconsistent evidence for pain, and a clear negative in acute fracture healing. Anything beyond that is being sold ahead of its data.
What we are and are not saying
| Claim | Our line |
|---|---|
| PEMF treats, cures or prevents disease | Never |
| A double-blind trial found reduced knee pain and 26% stopping NSAIDs | Yes, with the WOMAC interval crossing zero stated |
| Pooled trials found improved physical function | Yes, WMD -5.28 |
| Pooled trials found reduced pain | No. Four pain and stiffness outcomes all missed significance |
| It helps fractures heal | No. 259 patients, double blind, risk ratio 1.02 |
| The right dose is known | No. The reviewers say so themselves |
The practical part
The trials that found anything used long daily exposures: 12 hours a day for a month in the knee study, 10 hours a day for 12 weeks in the fracture study, where real-world compliance averaged 6.2 hours.
That matters if you are looking at a device sold on twenty minute sessions. It is not the protocol that produced these results.
One safety note. PEMF looks low risk, with no adverse events in the knee trial. The exception worth naming is anyone with an implanted electrical device such as a pacemaker or defibrillator, who should ask before going near one.
Where the design shows up
Bone and cartilage are not inert scaffolding. They respond to load, to electrical signalling, to use. That is why an astronaut loses bone density and a tennis player’s serving arm gains it.
The idea behind PEMF is not exotic: tissue that responds to physical signals might respond to an applied one. Whether the applied version is a good enough imitation of the real thing is what the trials keep arguing about, and the honest answer is that it depends which tissue and which outcome.
The load-bearing signal, meanwhile, is still free. It is called using the joint.
“The plans of the diligent certainly lead to advantage, but everyone who is hasty certainly comes to poverty.” Proverbs 21:5, NASB
The verse carries the conviction. Three trials and 740 patients carry three different answers.
What to do this week
If you have knee osteoarthritis, the movement evidence outruns the device evidence.
Loading the joint, strengthening the muscle around it and losing weight where relevant have far stronger and more consistent data than any panel or mat, and they cost nothing.
If you are considering PEMF anyway, ask what the trials used: hours a day, for weeks. And ask what parameters the device runs, knowing that even the reviewers cannot tell you which ones are correct.
Read this next: how we grade a field where the trials disagree like this: two of medicine’s top editors say you can’t believe much of it. And the therapy on our floor with the strongest human outcome data behind it: men who used a sauna 4 to 7 times a week had 63% fewer sudden cardiac deaths.
Sources
- Bagnato GL, Miceli G, Marino N, Sciortino D, Bagnato GF. “Pulsed electromagnetic fields in knee osteoarthritis: a double blind, placebo-controlled, randomized clinical trial.” Rheumatology, 2016;55(4):755-762. https://pubmed.ncbi.nlm.nih.gov/26705327/
- Chen L, Duan X, Xing F, et al. “Effects of pulsed electromagnetic field therapy on pain, stiffness and physical function in patients with knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.” Journal of Rehabilitation Medicine, 2019;51(11):821-827. https://pubmed.ncbi.nlm.nih.gov/31583420/
- Adie S, Harris IA, Naylor JM, et al. “Pulsed electromagnetic field stimulation for acute tibial shaft fractures: a multicenter, double-blind, randomized trial.” The Journal of Bone and Joint Surgery, 2011;93(17):1569-1576. https://pubmed.ncbi.nlm.nih.gov/21915570/
Article metadata retrieved from PubMed. Photograph from Pexels. Scripture quoted from the New American Standard Bible.
Educational content from True Health Solutions. We do not diagnose or prescribe, and nothing here is a substitute for care from someone who knows your history. The body heals. We write about what supports that design.
Questions people ask
- Does PEMF therapy work?
- It depends what for. A double-blind placebo-controlled trial in 60 knee osteoarthritis patients found significant pain reduction after a month of 12 hour daily use. A meta-analysis of 8 trials in 421 patients found improvement in physical function but no significant advantage for pain or stiffness. A 259 patient trial in acute tibial fractures found nothing at all.
- How long did people use it for?
- In the knee trial, a wearable device worn 12 hours daily for one month. In the fracture trial, 10 hours daily for 12 weeks, with average real-world use of 6.2 hours. These are not short exposures.
- Did it reduce medication use?
- In the knee trial, 26% of patients in the PEMF group stopped their NSAID or analgesic therapy. That is a patient-relevant outcome rather than a scale score, which is why we lead with it.
- Why do the studies disagree?
- Different conditions, different devices, different parameters. The meta-analysis authors say plainly that further trials are needed to determine the optimal parameters and treatment regimen, which is a polite way of saying nobody has settled what dose is correct.
- Is it safe?
- No adverse events were detected in the knee trial. PEMF is generally regarded as low risk, though anyone with an implanted electrical device such as a pacemaker needs to ask before going near one.
